BORIANI, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 73.040
EU - Europa 21.865
AS - Asia 7.019
SA - Sud America 127
OC - Oceania 66
Continente sconosciuto - Info sul continente non disponibili 46
AF - Africa 32
Totale 102.195
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 72.427
GB - Regno Unito 8.369
IT - Italia 4.059
CN - Cina 2.798
SE - Svezia 2.601
DE - Germania 2.495
HK - Hong Kong 1.923
TR - Turchia 1.822
UA - Ucraina 1.729
BG - Bulgaria 850
FI - Finlandia 460
FR - Francia 444
BZ - Belize 400
IE - Irlanda 201
RU - Federazione Russa 163
CA - Canada 160
IN - India 98
NL - Olanda 82
ES - Italia 80
PL - Polonia 75
JP - Giappone 74
AU - Australia 58
BE - Belgio 54
MY - Malesia 47
BR - Brasile 40
MX - Messico 40
VN - Vietnam 39
EU - Europa 36
RO - Romania 35
CH - Svizzera 33
SG - Singapore 33
CL - Cile 27
IR - Iran 26
GE - Georgia 24
GR - Grecia 24
CO - Colombia 23
IL - Israele 21
TW - Taiwan 19
CZ - Repubblica Ceca 17
PH - Filippine 15
RS - Serbia 15
AR - Argentina 12
KR - Corea 12
AT - Austria 11
DK - Danimarca 10
HU - Ungheria 10
PT - Portogallo 10
TH - Thailandia 10
A2 - ???statistics.table.value.countryCode.A2??? 9
EG - Egitto 9
ID - Indonesia 9
NZ - Nuova Zelanda 8
PE - Perù 8
EC - Ecuador 7
NO - Norvegia 7
IQ - Iraq 6
MD - Moldavia 6
BD - Bangladesh 5
CU - Cuba 5
KZ - Kazakistan 5
PK - Pakistan 5
SA - Arabia Saudita 5
SI - Slovenia 5
SK - Slovacchia (Repubblica Slovacca) 5
VE - Venezuela 5
ZA - Sudafrica 5
CR - Costa Rica 4
GH - Ghana 4
LT - Lituania 4
UG - Uganda 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
BT - Bhutan 3
DO - Repubblica Dominicana 3
JO - Giordania 3
LK - Sri Lanka 3
MK - Macedonia 3
PS - Palestinian Territory 3
UY - Uruguay 3
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
DZ - Algeria 2
EE - Estonia 2
LA - Repubblica Popolare Democratica del Laos 2
NP - Nepal 2
TN - Tunisia 2
TZ - Tanzania 2
AP - ???statistics.table.value.countryCode.AP??? 1
AZ - Azerbaigian 1
BJ - Benin 1
CY - Cipro 1
ET - Etiopia 1
GL - Groenlandia 1
HR - Croazia 1
KE - Kenya 1
KH - Cambogia 1
LB - Libano 1
MA - Marocco 1
Totale 102.195
Salva come PNG Salva come JPEG
Città #
Fairfield 12.851
Woodbridge 7.524
Southend 7.258
Houston 5.829
Ashburn 5.697
Seattle 4.936
Cambridge 4.149
Chandler 4.145
Wilmington 4.073
Jacksonville 3.635
Ann Arbor 2.815
Dearborn 2.335
Hong Kong 1.875
Nyköping 1.463
Modena 1.404
Beijing 1.244
San Diego 1.244
Izmir 1.214
New York 1.104
Princeton 893
Sofia 848
San Jose 846
Eugene 729
Belize City 400
London 395
Helsinki 318
Dallas 308
Falls Church 256
Milan 233
Boardman 209
Fremont 187
Chicago 183
Dublin 178
Saint Louis 169
Bologna 163
Norwalk 163
Rome 154
Las Vegas 135
Albuquerque 133
Hefei 128
Redwood City 120
Kunming 114
Atlanta 111
Nanjing 107
Kilburn 100
Columbus 94
Grafing 75
Shanghai 74
Toronto 66
Jinan 63
Chiswick 61
Guangzhou 55
Prescot 51
Florence 50
Hounslow 48
Nanchang 47
Naples 45
Saint Petersburg 45
Sergii 43
Turin 42
Brussels 41
Des Moines 36
Fuzhou 36
Philadelphia 36
San Giuliano Milanese 35
Bremen 31
Parma 31
Acton 29
Central 29
Munich 29
Shenyang 29
Islington 28
Esslingen am Neckar 27
Milwaukee 27
San Francisco 27
Ottawa 26
Lappeenranta 25
Tokyo 25
Wandsworth 25
Dong Ket 24
Forlimpopoli 24
Mountain View 22
Verona 22
Zhengzhou 22
Singapore 20
Wuhan 20
Hebei 19
North York 19
Paris 19
Indiana 18
San Mateo 18
Sydney 18
Xian 18
Brescia 17
Chongqing 17
Forlì 17
Napoli 17
Perugia 17
Southwark 17
São Paulo 17
Totale 84.208
Salva come PNG Salva come JPEG
Nome #
Long-Term Implications of Atrial Fibrillation in Patients With Degenerative Mitral Regurgitation 545
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC (Eur Heart J (2021) 42 (373–498) DOI: 10.1093/eurheartj/ehaa612) 342
Registro Italiano Pacemaker e Defibrillatori: Bollettino Periodico 2016 Associazione Italiana di Aritmologia e Cardiostimolazione 280
The future of continuing medical education: the roles of medical professional societies and the health care industry: Position paper prepared with contributions from the European Society of Cardiology Committees for Advocacy, Education and Industry Relations, Endorsed by the Board of the European Society of Cardiology 260
La sindrome da pacemaker. 259
Prevalence and clinical significance of left bundle branch block according to classical or strict definition criteria in permanent pacemaker patients 250
Linee guida AIAC all'impianto di pacemaker, dispositivi per la resincronizzazione cardiaca, defibrillatori automatici e loop recorder. Update 2011. 249
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial 246
Screening for atrial fibrillation: A Report of the AF-SCREEN International Collaboration 241
2018 EHRA expert consensus statement on lead extraction: Recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: Endorsed by APHRS/HRS/LAHRS 239
Clinically guided pacemaker choice and setting: pacemaker expert programming study 225
Guía de práctica clínica de la ESC 2013 sobre estimulación cardiaca y terapia de resincronización cardiaca 211
The 2018 European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Executive summary 210
Implantable cardioverter-defibrillator–computed respiratory disturbance index accurately identifies severe sleep apnea: The DASAP-HF study 209
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report 207
108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, The Netherlands. 206
Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol 206
Role of the tricuspid regurgitation after mitraclip and transcatheter aortic valve implantation: a systematic review and meta-analysis 204
Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation 203
'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: The EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry 200
Letter by Gasparini and Boriani Regarding Article, "Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation: Results From the Resynchronization for Ambulatory Heart Failure Trial (RAFT)" 198
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA) 197
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 197
P wave dispersion and short-term vs. late atrial fibrillation recurrences after cardioversion 197
QRS interval time-related changes and prognosis in heart failure 194
Home care for heart failure: can caregiver education prevent hospital admissions? A randomized trial in primary care 194
Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden 193
2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing 190
Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations 189
Prediction of cardiac resynchronization therapy response: value of calibrated integrated backscatter imaging. 188
The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden 185
Cardiac device therapy in patients with left ventricular dysfunction and heart failure: ‘real-world’ data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital) 184
QRS pattern and improvement in right and left ventricular function after cardiac resynchronization therapy: a radionuclide study 184
Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF 184
Remote Monitoring of Patients with an Implanted Device and Patients' Outcomes: The Potential for "Win-Win" Dynamics. 184
'Real-world' atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase 181
Emery-Dreifuss Muscular Dystrophy-Associated Mutant Forms of Lamin A Recruit the Stress Responsive Protein Ankrd2 into the Nucleus, Affecting the Cellular Response to Oxidative Stress 181
Risk stratification of cardiovascular and heart failure hospitalizations using integrated device diagnostics in patients with a cardiac resynchronization therapy defibrillator 181
Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. 180
Health economics and the European Heart Rhythm Association. 180
Cardiac resynchronization therapy: is systole all that matters? 180
Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation 180
Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples 180
EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation 180
Cardiac involvement in systemic sclerosis: identification of high-risk patient profiles in different patterns of clinical presentation 178
12-year Temporal Trend in Referral Pattern and Test Results of Stress Echocardiography in a Tertiary Care Referral Center with Moderate Volume Activities and Cath-lab Facility 178
Decrease in patient radiation exposure by a tantalum filter during electrophysiological procedures. 177
The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) Randomized Controlled Trial: Phase 1 Results on Dynamics of Early Intervention With Remote Monitoring 177
Implantable dual-chamber defibrillator for the selective treatment of spontaneous atrial and ventricular arrhythmias: arrhythmia incidence and device performance. 177
Randomized comparison between Ramp and Burst+ atrial antitachycardia pacing therapies in patients suffering from sinus node disease and atrial fibrillation and implanted with a DDDRP device. 177
Validation of a simple risk stratification tool for patients implanted with Cardiac Resynchronization Therapy: The VALID-CRT risk score 176
Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry 176
The wearable cardioverter-defibrillator: Current technology and evolving indications 176
Inappropriate shock for myopotential over-sensing in a patient with subcutaneous ICD 175
Management of Phrenic Stimulation in CRT Patients over the Long Term: Still an Unmet Need ? 175
Asymptomatic lone atrial fibrillation - how can we detect the arrhythmia? 175
Cardiac resynchronization therapy in the real world: need to focus on implant rates, patient selection, co-morbidities, type of devices, and complications 175
Beta-blocker treatment guided by head-up tilt test in neurally mediated syncope 175
Elevated TGF β2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes 175
Extending survival by reducing sudden death with implantable cardioverter-defibrillators: a challenging clinical issue in non-ischaemic and ischaemic cardiomyopathies 175
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 174
Cardiac resynchronization therapy in the real world: need to upgrade outcome research 174
Health care cost analysis of enhanced pacing modalities in bradycardia patients: Portuguese case study on the results of the MINERVA trial 173
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary 173
Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: Results of markov modelling in a european population 172
Reducing unnecessary right ventricular pacing with the managed ventricular pacing mode in patients with sinus node disease and AV block. 172
The QRS interval in patients treated with resynchronization therapy: which value? 171
Far-field R wave oversensing in dual-chamber pacemakers designed for atrial arrhythmia management: effect of pacing site and lead tip to ring distance 171
Rhythm discrimination by rate branch and QRS morphology in dual chamber implantable cardioverter defibrillators 171
Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants 171
Effect of high-pass filtering on ECG signal on the analysis of patients prone to atrial fibrillation 170
Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy 170
Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. 170
A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial. 170
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 170
New classification of geometric patterns considering left ventricular volume in patients with chronic aortic valve regurgitation: Prevalence and association with adverse cardiovascular outcomes 170
Ventricular fibrillation during sleep in an adolescent with hypertrophic cardiomyopathy: the difficulty of risk stratification and the power of the cardioverter-defibrillator 170
Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling 169
Cardiac resynchronization by pacing: an electrical treatment of heart failure 169
Cardiac resynchronization therapy: effects on left and right ventricular ejection fraction during exercise. 169
Cardiac tachyarrhythmias and patient values and preferences for their management: The European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 169
Role of ventricular Autocapture function in increasing longevity of DDDR pacemakers: a prospective study. 169
Cardiac resynchronization therapy and electrical storm: results of the OBSERVational registry on long-term outcome of ICD patients (OBSERVO-ICD) 169
Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes 169
P-wave characteristics after electrical external cardioversion: Predictive indexes of relapse 169
Combined use of morphology discrimination, sudden onset, and stability as discriminating algorithms in single chamber cardioverter defibrillators 168
Atrial evoked response integral for automatic capture verification in atrial pacing 168
Occupational radiation exposure in the electrophysiology laboratory with a focus on personnel with reproductive potential and during pregnancy: A European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS) 168
Can we predict new AF occurrence in single-chamber ICD patients? Insights from an observational investigation 168
Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action 168
Heart failure after myocardial revascularization: Risk markers 167
Oral loading of propafenone: restoring its role before restoring rhythm 167
New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial 167
Cardiac resynchronization and implantable cardioverter defibrillator therapy: Preliminary results from the InSync Implantable Cardioverter Defibrillator Italian Registry 167
Implant rates of cardiac implantable electrical devices in Europe: A systematic literature review 167
Serial versus isolated assessment of clinical and instrumental parameters in heart failure: Prognostic and therapeutic implications 167
The empowerment of translational research: lessons from laminopathies 166
Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy 166
The Italian subcutaneous implantable cardioverter-defibrillator survey: S-ICD, why not? 166
Atrial fibrillation prevention: An appraisal of current evidence 166
Totale 19.060
Salva come PNG Salva come JPEG
Categoria #
all - tutte 440.544
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 440.544
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20197.505 0 0 0 0 0 0 0 0 0 1.028 2.733 3.744
2019/202028.588 1.476 794 1.256 3.361 2.837 4.693 5.403 2.518 3.021 1.172 1.531 526
2020/202122.437 1.993 841 2.000 2.486 2.603 1.348 2.848 2.882 1.051 2.005 1.309 1.071
2021/202215.465 664 1.848 1.677 712 427 1.286 887 786 1.655 1.369 2.411 1.743
2022/202311.536 1.660 974 714 826 1.469 1.536 259 1.187 1.758 206 597 350
2023/20248.525 393 632 435 803 2.283 1.440 447 1.696 223 173 0 0
Totale 105.250